In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors

European Journal of Clinical Pharmacology

Volumn 50, Issue 3, 1996, Pages 209-215

  Transon, C ^a   Leemann, T ^a   Dayer, P ^a  

^a University Hospital   (Switzerland)

Author keywords

CYP2C9 inhibition; CYP2D6 inhibition; CYP3A4 inhibition; HMG CoA reductase inhibitors; drug interactions; Human liver microsomes

Indexed keywords

CYTOCHROME P450 ISOENZYME; DEXTROMETHORPHAN; DICLOFENAC; DRUG METABOLIZING ENZYME; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MIDAZOLAM; PRAVASTATIN; SIMVASTATIN;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FATTY ACIDS, MONOUNSATURATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; ISOENZYMES; LOVASTATIN; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; PRAVASTATIN; SIMVASTATIN; STEREOISOMERISM; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0030004755     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050094     Document Type: Article

References (45)

1. Duggan DE, Vickers S (1990) Physiological disposition of HMG-CoA-reductase inhibitors. Drug Metab Rev 22:333-362
2. Ahmad S (1990) Lovastatin-warfarin interaction. Arch Intern Med 150:2407
3. Walker JF (1989) Simvastatin: the clinical profile. Am J Med 87:445-465
4. Hartmann K, Kuhn M, Gartmann J (1992) Simvastatine et pravastatine: ces nouveaux hypolipidémiants, inhibiteurs de la synthèse du cholestérol, sous la loupe du CSPV. Bull Méd Suisses 49:1915-1917
5. Feely J, O'Connor P (1991) Effects of HMG CoA reductase inhibitors on warfarin binding. Drug Invest 5:315-316
6. Rolan PE (1994) Plasma protein binding displacement interactions Why are they still regarded as clinically important? Br J Clin Pharmacol 37:125-128
7. Rettie AE, Korzekwa KR, Kunze KL, et al (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P450: a role for P4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5:54-59
8. Hermans JJR, Thijssen HHW (1993) Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br J Pharmacol 110:482-490
9. Von Bahr C, Groth CG, Jansson H, et al (1980) Drug metabolism in human liver in vitro: Establishment of a human liver bank. Clin Pharmacol Ther 27:711-725
10. Dayer P, Kronbach T, Eichelbaum M, Meyer UA (1987) Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Biochem Pharmacol 36:4145-4152
11. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275
12. Leemann T, Transon C, Dayer P (1993) Diclofenac 4′-hydroxylation by cytochrome P450TB (CYP2C) in human liver. Life Sci 52:29-34
13. Dayer P, Leemann T, Striberni R (1989) Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P450db1 activity. Clin Pharmacol Ther 45:34-40
14. Gascon MP, Dayer P (1991) In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 41:573-578
15. Holford NHG (1991) MKMODEL (version 4.42) User Manual. Cambridge: Biosoft
16. Dixon M (1953) The determination of enzyme inhibitor constants. Biochem J 55:170-171
17. Cornish-Bowden A (1974) A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. Biochem J 137:143-144
18. Illingworth DR, Erkelens DW, Keller U, Thompson GR, Tikkanen MJ (1993) Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin. Lancet 343:1554-1555
19. Blum CB (1994) Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 73:3D-11D
20. Tse FLS, Jaffe JM, Troendle A (1992) Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 32:630-638
21. Smith HT, Jokubaitis LA, Troendle AJ, Hwang DS, Robinson WT (1993) Pharmacokinetics of fluvastatin and specific drug interactions. Am J Hypertens 6:375S-382S
22. Tse FLS, Nickerson DF, Yardley WS (1993) Binding of fluvastatin to blood cells and plasma proteins. J Pharm Sci 82:942-947
23. Pan HY, Triscari J, DeVault AR, et al (1991) Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin. Br J Clin Pharmacol 31:665-670
24. Duggan DE, Chen IW, Bayne WF, et al (1989) The physiological disposition of lovastatin. Drug Metab Dispos 17:166-173
25. Pan HY, DeVault AR, Wang-Iverson D, Ivashkiv L, Swanson BN, Sugerman AA (1990) Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacor 30:1128-1135
26. Botti RE, Triscari J, Pan HY, Zayat J (1991) Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol 14:256-261
27. Singhvi SM, Pan HY, Morrison RA, Willard DA (1990) Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 29:239-243
28. Pan HY, DeVault AR, Swites BJ, et al (1990) Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther 48:201-207
29. Triscari J, Swanson BN, Willard DA, Cohen AI, DeVault A, Pan HY (1993) Steady state serum concentrations of pravastatin and digoxin when given in combination. Br J Clin Pharmacol 36:263-265
30. Vickers S, Duncan CA, Chen IW, Rosegay A, Duggan DE (1990) Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 18:138-145
31. Mauro VF (1993) Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 24:195-202
32. Smith DA, Jones BC (1992) Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 44:2089-2098
33. Serajuddin ATM, Ranadive SA, Mahoney EM (1991) Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J Pharm Sci 80:830-834
34. Guillot F, Misslin P, Lemaire M (1993) Comparison of fluvastatin blood-brain barrier transfer using in vitro and in vivo methods. J Cardiovasc Pharmacol 21:339-346
35. Mahoney EM, Child MJ, Smith-Monroy CA (1990) Differential transport of pravastatin and lovastatin by hepatocytes and fibroblasts. Circulation 82:Abstract 23
36. Zeigler K, Stünkel W (1992) Tissue-selective action of pravastatin due to hepatocellular uptake via a sodium-independent bile acid transporter. Biochim Biophys Acta 1139:203-209
37. Yamazaki M, Suzuki H, Hanano M, Tokui T, Komai T, Sugiyama Y (1993) Na+-dependent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol 264:G36-G44
38. Ziegler K, Hummelsiep S (1993) Hepatoselective carrier-mediated sodium-independent uptake of pravastatin and pravastatin-lactone. Biochim Biophys Acta 1153:23-33
39. LeBlanc GA (1994) Hepatic vectorial transport of xenobiotics. Chem-Biol Interact 90:101-120
40. Wang RW, Kari PH, Lu AYH, et al (1991) Biotransformation of lovastatin. IV. Identification of cytochrome P4503A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 290:355-361
41. Franklin MR (1991) Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. Methods Enzymol 206:559-573
42. Periti P, Mazzei T, Mini E, Novelli A (1992) Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 23: 106-131
43. Hassel D, Utt JK (1985) Suspected interaction. Warfarin and erythromycin. South Med J 78:1015-1016
44. Gaw A, Wosornu D (1992) Simvastatin during warfarin therapy in hyperlipoproteinaemia. Lancet 340:979-980
45. Transon C, Leemann T, Vogt N, Dayer P (1995). In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin. Clin Pharmacol Ther 58:412-417